The effect of oral metformin on insulin sensitivity in insulin-resistant ponies

Kellie Tinworth, Ray C. Boston, Patricia A. Harris, Martin Sillence, Sharanne Raidal, Glenys Noble

Research output: Contribution to journalArticle

30 Citations (Scopus)
35 Downloads (Pure)

Abstract

Metformin may be an effective therapeutic option for insulin-resistant (I-R) horses/ponies because, in humans, it reportedly enhances insulin sensitivity (SI) of peripheral tissues without stimulating insulin secretion. To determine the effect of metformin on insulin and glucose dynamics in I-R ponies, six ponies were studied in a cross-over design by Minimal Model analysis of a frequently-sampled intravenous glucose tolerance test (FSIGT). Metformin was administered at 15 mg/kg bodyweight (BW), orally, twice-daily, for 21 days to the metformin-treated group. The control group received a placebo. A FSIGT was conducted before and after treatment. The Minimal Model of glucose and insulin dynamics rendered indices describing SI, glucose effectiveness (Sg), acute insulin response to glucose (AIRg) and the disposition index (DI). The body condition score (BCS), BW and cresty neck score (CNS) were also assessed.There was no significant change in SI, Sg, AIRg, DI, BW, BCS or CNS in response to metformin, or over time in the control group. There were no measurable benefits of metformin on SI, consistent with recent work showing that the bioavailability of metformin in horses is poor, and chronic dosing may not achieve therapeutic blood concentrations. Alternatively, metformin may only be effective in obese ponies losing weight or with hyperglycaemia.
Original languageEnglish
Pages (from-to)79-84
Number of pages6
JournalVeterinary Journal
Volume191
Issue number1
DOIs
Publication statusPublished - Jan 2012

Fingerprint

metformin
Metformin
insulin resistance
Insulin Resistance
mouth
Insulin
horses
Glucose
glucose
insulin
Glucose Tolerance Test
Horses
neck
body condition
body weight
Neck
therapeutics
Control Groups
insulin secretion
hyperglycemia

Cite this

Tinworth, Kellie ; Boston, Ray C. ; Harris, Patricia A. ; Sillence, Martin ; Raidal, Sharanne ; Noble, Glenys. / The effect of oral metformin on insulin sensitivity in insulin-resistant ponies. In: Veterinary Journal. 2012 ; Vol. 191, No. 1. pp. 79-84.
@article{a36203da420a4733803e838856763cc9,
title = "The effect of oral metformin on insulin sensitivity in insulin-resistant ponies",
abstract = "Metformin may be an effective therapeutic option for insulin-resistant (I-R) horses/ponies because, in humans, it reportedly enhances insulin sensitivity (SI) of peripheral tissues without stimulating insulin secretion. To determine the effect of metformin on insulin and glucose dynamics in I-R ponies, six ponies were studied in a cross-over design by Minimal Model analysis of a frequently-sampled intravenous glucose tolerance test (FSIGT). Metformin was administered at 15 mg/kg bodyweight (BW), orally, twice-daily, for 21 days to the metformin-treated group. The control group received a placebo. A FSIGT was conducted before and after treatment. The Minimal Model of glucose and insulin dynamics rendered indices describing SI, glucose effectiveness (Sg), acute insulin response to glucose (AIRg) and the disposition index (DI). The body condition score (BCS), BW and cresty neck score (CNS) were also assessed.There was no significant change in SI, Sg, AIRg, DI, BW, BCS or CNS in response to metformin, or over time in the control group. There were no measurable benefits of metformin on SI, consistent with recent work showing that the bioavailability of metformin in horses is poor, and chronic dosing may not achieve therapeutic blood concentrations. Alternatively, metformin may only be effective in obese ponies losing weight or with hyperglycaemia.",
keywords = "Open access version available, Equine, Hyperinsulinaemia, Laminitis, Obesity, Pharmacology",
author = "Kellie Tinworth and Boston, {Ray C.} and Harris, {Patricia A.} and Martin Sillence and Sharanne Raidal and Glenys Noble",
note = "Imported on 12 Apr 2017 - DigiTool details were: month (773h) = January 2012; Journal title (773t) = The Veterinary Journal. ISSNs: 1090-0233;",
year = "2012",
month = "1",
doi = "10.1016/j.tvjl.2011.01.015",
language = "English",
volume = "191",
pages = "79--84",
journal = "The Veterinary Journal",
issn = "1090-0233",
publisher = "Bailliere Tindall Ltd",
number = "1",

}

The effect of oral metformin on insulin sensitivity in insulin-resistant ponies. / Tinworth, Kellie; Boston, Ray C.; Harris, Patricia A.; Sillence, Martin; Raidal, Sharanne; Noble, Glenys.

In: Veterinary Journal, Vol. 191, No. 1, 01.2012, p. 79-84.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The effect of oral metformin on insulin sensitivity in insulin-resistant ponies

AU - Tinworth, Kellie

AU - Boston, Ray C.

AU - Harris, Patricia A.

AU - Sillence, Martin

AU - Raidal, Sharanne

AU - Noble, Glenys

N1 - Imported on 12 Apr 2017 - DigiTool details were: month (773h) = January 2012; Journal title (773t) = The Veterinary Journal. ISSNs: 1090-0233;

PY - 2012/1

Y1 - 2012/1

N2 - Metformin may be an effective therapeutic option for insulin-resistant (I-R) horses/ponies because, in humans, it reportedly enhances insulin sensitivity (SI) of peripheral tissues without stimulating insulin secretion. To determine the effect of metformin on insulin and glucose dynamics in I-R ponies, six ponies were studied in a cross-over design by Minimal Model analysis of a frequently-sampled intravenous glucose tolerance test (FSIGT). Metformin was administered at 15 mg/kg bodyweight (BW), orally, twice-daily, for 21 days to the metformin-treated group. The control group received a placebo. A FSIGT was conducted before and after treatment. The Minimal Model of glucose and insulin dynamics rendered indices describing SI, glucose effectiveness (Sg), acute insulin response to glucose (AIRg) and the disposition index (DI). The body condition score (BCS), BW and cresty neck score (CNS) were also assessed.There was no significant change in SI, Sg, AIRg, DI, BW, BCS or CNS in response to metformin, or over time in the control group. There were no measurable benefits of metformin on SI, consistent with recent work showing that the bioavailability of metformin in horses is poor, and chronic dosing may not achieve therapeutic blood concentrations. Alternatively, metformin may only be effective in obese ponies losing weight or with hyperglycaemia.

AB - Metformin may be an effective therapeutic option for insulin-resistant (I-R) horses/ponies because, in humans, it reportedly enhances insulin sensitivity (SI) of peripheral tissues without stimulating insulin secretion. To determine the effect of metformin on insulin and glucose dynamics in I-R ponies, six ponies were studied in a cross-over design by Minimal Model analysis of a frequently-sampled intravenous glucose tolerance test (FSIGT). Metformin was administered at 15 mg/kg bodyweight (BW), orally, twice-daily, for 21 days to the metformin-treated group. The control group received a placebo. A FSIGT was conducted before and after treatment. The Minimal Model of glucose and insulin dynamics rendered indices describing SI, glucose effectiveness (Sg), acute insulin response to glucose (AIRg) and the disposition index (DI). The body condition score (BCS), BW and cresty neck score (CNS) were also assessed.There was no significant change in SI, Sg, AIRg, DI, BW, BCS or CNS in response to metformin, or over time in the control group. There were no measurable benefits of metformin on SI, consistent with recent work showing that the bioavailability of metformin in horses is poor, and chronic dosing may not achieve therapeutic blood concentrations. Alternatively, metformin may only be effective in obese ponies losing weight or with hyperglycaemia.

KW - Open access version available

KW - Equine

KW - Hyperinsulinaemia

KW - Laminitis

KW - Obesity

KW - Pharmacology

U2 - 10.1016/j.tvjl.2011.01.015

DO - 10.1016/j.tvjl.2011.01.015

M3 - Article

VL - 191

SP - 79

EP - 84

JO - The Veterinary Journal

JF - The Veterinary Journal

SN - 1090-0233

IS - 1

ER -